VQW-765

• CAT Number: I002647
• CAS Number: 669770-29-0
• Molecular Formula: C19H22N2O
• Molecular Weight: 294.39
• Purity: ≥95%
• Synonyms: (3R)-3-[6-(4-methylphenyl)pyridin-3-yl]oxy-1-azabicyclo[2.2.2]octane
• InChI: InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
• InChIKey: NPDLTEZXGWRMLQ-IBGZPJMESA-N
• SMILES: CC1=CC=C(C=C1)C2=NC=C(C=C2)OC3CN4CCC3CC4

VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pKD value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety[1].
VQW-765 shows a binding efficacy with a pKD value of 7.56 to recombinantly expressed human α7-nACh receptor[1].
VQW-765 shows a potent agonist activity to calcium transients that detected after stimulation of human α7-nACh receptors recombinantly expressed in GH3-ha7-22 cells with a pEC50 value of 7.41[1].
VQW-765 (0.03 and 0.3 mg/kg; oral administration once) increases cognitive effect and learning/memory performance in mice[1].
VQW-765 (1 mg/kg; oral administration once) shows anxiolytic-like effect with increasing the social exploration time in rats with a duration of at least 6 h[1].

Reference

[1]. Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172(5):1292-304.
 [Content Brief]